Syncona Says Beacon Therapeutics Delivers Positive Topline Result In Phase II/III Vista Trial

By Reuters News

- Syncona Ltd SYNCS.L:

  • SYNCONA LIMITED - BEACON DELIVERS POSITIVE TOPLINE PII/III RESULTS

  • SYNCONA - BEACON THERAPEUTICS DELIVERS POSITIVE TOPLINE RESULT IN PHASE II/III VISTA TRIAL

  • SYNCONA - BEACON TO INITIATE PRE-SUBMISSION DISCUSSIONS WITH GLOBAL REGULATORY AUTHORITIES

  • SYNCONA - BEACON TO INITIATE ROLLING BLA SUBMISSION LATER THIS YEAR

  • SYNCONA - LARU-ZOVA MEETS FDA-ENDORSED PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT LLVA

Further company coverage: SYNCS.L

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk